Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Cancer Vaccines

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...

Adaptive Mechanisms in Cancer Cells

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...

Adaptive Mechanisms in Cancer Cells

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Plant Functional Groups Mediated the Effects of Plateau Pika Disturbance and Mowing on the Community Stability of Alpine Meadow Plants.

Ecology and evolution·2026

Same author

Drivers of moss community assembly and heavy metal accumulation in a lead-zinc mining area.

Environmental geochemistry and health·2026

Same author

Synergistic Effects of Biodegradable Microplastics and Herbicide on Plant Growth and Soil Carbon Processes in Karst Agricultural Ecosystems.

Journal of agricultural and food chemistry·2026

Same author

Physiological priority over morphological growth: a resource trade-off strategy of the moss Hydrogonium majusculum (C. Muell.) Chen in petrifying spring tufa.

BMC plant biology·2026

Same author

Characteristics of missing incidents and risk factors for harm for older people with and without dementia in the UK.

Age and ageing·2026

Same author

<i>Bifidobacterium animalis</i> suppresses melanoma progression and activates anti-tumor immunity by inhibiting YAP1 expression in CD8+ T cells.

Cancer biology & medicine·2026

Search research articles

Related Experiment Video

Updated: Jul 17, 2026

Non-Viral Engineering of Primary Human T Cells via Homology-Mediated End-Joining Targeted Integration of Large DNA Templates

Non-Viral Engineering of Primary Human T Cells via Homology-Mediated End-Joining Targeted Integration of Large DNA Templates

Published on: May 9, 2025

Strategic engineering B cell immunity for cancer immunotherapy.

Chengyi Li¹, Hrishi Venkatesh¹, Lam Trieu¹

¹Immunotherapy Integrated Research Center, Fred Hutchinson Cancer Center, Seatle, WA, USA.

Journal of Controlled Release : Official Journal of the Controlled Release Society

|July 15, 2026

Summary

B cells within tumors are linked to better patient responses to immune checkpoint blockade therapy. Targeting B cell presence and tertiary lymphoid structures (TLS) may enhance anti-tumor immunity and improve cancer treatment outcomes.

Keywords:

Anti-tumor Antibody secretion Antigen presentation B cell immunity Immune substance production Immunotherapy Pro-tumor Tertiary lymphoid structure Tumor contexture

More Related Videos

Dissociation of Human and Mouse Tumor Tissue Samples for Single-cell RNA Sequencing

Dissociation of Human and Mouse Tumor Tissue Samples for Single-cell RNA Sequencing

Published on: August 16, 2024

A Syngeneic Mouse B-Cell Lymphoma Model for Pre-Clinical Evaluation of CD19 CAR T Cells

A Syngeneic Mouse B-Cell Lymphoma Model for Pre-Clinical Evaluation of CD19 CAR T Cells

Published on: October 16, 2018

Related Experiment Videos

Last Updated: Jul 17, 2026

Non-Viral Engineering of Primary Human T Cells via Homology-Mediated End-Joining Targeted Integration of Large DNA Templates

Non-Viral Engineering of Primary Human T Cells via Homology-Mediated End-Joining Targeted Integration of Large DNA Templates

Published on: May 9, 2025

Dissociation of Human and Mouse Tumor Tissue Samples for Single-cell RNA Sequencing

Dissociation of Human and Mouse Tumor Tissue Samples for Single-cell RNA Sequencing

Published on: August 16, 2024

A Syngeneic Mouse B-Cell Lymphoma Model for Pre-Clinical Evaluation of CD19 CAR T Cells

A Syngeneic Mouse B-Cell Lymphoma Model for Pre-Clinical Evaluation of CD19 CAR T Cells

Published on: October 16, 2018

Area of Science:

Oncology
Immunology
Cancer Research

Background:

Clinical data reveal a correlation between B-cell presence in tumors and improved patient outcomes after immune checkpoint blockade.
Mature tertiary lymphoid structures (TLS), characterized by distinct B and T cell zones, are associated with patient response to immunotherapy.

Purpose of the Study:

To investigate the context-dependent roles of B cell immunity (antibody secretion, antigen presentation, cytokine production) in anti- and pro-tumorigenic functions.
To understand the importance of B cell-mediated immunity for tumor control.

Main Methods:

Analysis of clinical datasets across various cancer types.
Review of existing clinical observations on tertiary lymphoid structures (TLS) and immunotherapy response.

Main Results:

B cell presence and mature TLS are key determinants of patient response to immune checkpoint blockade.
B cell functions like antibody secretion and antigen presentation play crucial roles in tumor control.

Conclusions:

Therapeutic strategies aimed at increasing B cell infiltration and TLS maturation hold promise for reprogramming the tumor microenvironment.
Enhancing B cell-mediated anti-tumor immunity can lead to improved tumor clearance and better patient survival in cancer immunotherapy.